Related Experiment Video
Updated: Oct 1, 2025

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Triple Antithrombotic Therapy (Triple Therapy) After Percutaneous Coronary Intervention in Chronic Anticoagulation: A
Ali Hussain1, Amjad Minhas2, Usman Sarwar3,4
1Internal Medicine, Sentara Albemarle Medical Center, Elizabeth City, USA.
Insights
Choosing anticoagulation for atrial fibrillation and coronary artery disease patients is complex. Triple therapy increases bleeding and mortality risk compared to dual therapy with an anticoagulant and P2Y12 inhibitor.
Area of Science:
- Cardiology
- Pharmacology
- Internal Medicine
Background:
- Managing patients with both atrial fibrillation and coronary artery disease requires careful consideration of antithrombotic therapy.
- Treatment strategies have evolved from warfarin to dual antiplatelet therapy.
Purpose of the Study:
- To review the evolution of anticoagulation strategies for patients with atrial fibrillation and coronary artery disease.
- To compare the risks and benefits of different antithrombotic regimens.
Main Methods:
- Literature review of historical and current treatment guidelines.
- Analysis of comparative effectiveness and safety data for various antithrombotic combinations.
Main Results:
- Warfarin was an early option for preventing stent thrombosis.
- Dual antiplatelet therapy is now the standard recommendation.
- Triple therapy (aspirin, P2Y12 inhibitor, oral anticoagulation) shows increased bleeding and mortality.
Conclusions:
- Triple therapy in this patient population is associated with significant risks.
- A combination of an anticoagulant and a P2Y12 inhibitor may offer a safer alternative.
Abstract:
Selecting anticoagulation therapy for patients with atrial fibrillation and coronary artery disease has always been challenging for physicians. The treatment modalities have evolved with time. Oral anticoagulation with warfarin was used in the initial era of stenting to prevent stent thrombosis, and dual antiplatelet therapy is the current recommendation. Triple anticoagulation therapy, i.e., aspirin, P2Y12 inhibitor, and oral anticoagulation, is associated with higher bleeding episodes and mortality compared to the combination of an anticoagulant and a P2Y12 inhibitor.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Peripheral Artery Disease III: Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Acute Coronary Syndrome IV: Interprofessional Care
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

